TSAO compounds: The comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase

Current Topics in Medicinal Chemistry

Volumn 4, Issue 9, 2004, Pages 945-963

  Camarasa, María José ^a   San Félix, Ana ^a   Velázquez, Sonsoles ^a   Pérez Pérez, María Jesús ^a   Gago, Federico ^b   Balzarini, Jan ^c  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Dimerization; Non nucleoside RT inhibitors; Resistance; Reverse transcriptase; TSAO compounds

Indexed keywords

1 (1H INDOL 2 YLCARBONYL) 4 [3 (ISOPROPYLAMINO)PYRIDINYL]PIPERAZINE; 1 [[2',5' BIS O (TERT BUTYLDIMETHYLSILYL) BETA DEXTRO RIBOFURANOSYL]THYMINE] 3' SPIRO 5'' (4'' AMINO 1'',2'' OXATHIOLE 2'',2'' DIOXIDE); 9 CHLORO 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; ABACAVIR; ADEFOVIR; ADEFOVIR DIPIVOXIL; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; FOSCARNET; LAMIVUDINE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; SPIRO COMPOUND;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG DESIGN; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR MODEL; NONHUMAN; PROTEIN FAMILY; REVIEW; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; VIRUS LOAD; VIRUS STRAIN; ANTIBIOTIC RESISTANCE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2942525968     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043388600     Document Type: Review

References (128)

1. Kinchington, D.; Gee, S.; Balzarini, J.; Gait, M.; de Clercq, E. Current antiviral agents FactFile: 1999-2000 update. Part II - Human immunodeficiency viruses. Int. Antiviral News 2000, 8, 4-21.
2. Balzarini, J.; De Clercq, E. Biochemical pharmacology. A. Nucleoside and nonnucleoside reverse transcriptase inhibitors active against HIV. In Merigan, T.C.; Bartlett, J.G.; Bolognesi, D. (Eds.), Textbook of AIDS Medicine Ch. 47 (pp. 815-847). Philadelphia: Williams & Wilkins. 1998.
3. Tavel, J.A.; Miller, K.D.; Masur, H. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Clin. Infect. Dis. 1999, 28, 643-676.
4. Balzarini, J.; and De Clercq, E. Biochemical pharmacology of analogs active against HIV. In T. C. Merigan, J. G. Bartlett, & S. Broder (Eds.), Textbook of AIDS Medicine Ch. 49 (pp. 751-772). Philadelphia: Williams & Wilkins. 1994.
5. De Clercq, E. New perspectives for the treatment of HIV infections. N. Trends Mediterranean J. Infect. Parasit. Dis. 1998, 13, 7-20.
6. De Clercq, E. Antiviral drugs: current state of the art. J. Clin. Virol. 2001, 22, 73-89.
7. De Clereq, E. New perspectives for the treatment of HIV infections. Verb K Acad Geneesk Belg. 1998, 60, 13-45.
8. Schinazi, R.F. Competitive inhibitors of human immunodeficiency virus reverse transcriptase. Perspect. Drug Discov. Des. 1993, 1, 151-180.
9. De Clercq, E. Towards improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491-2517.
10. Young, S.D. Nonnucleoside inhibitors of HIV-1 reverse transcriptase. Perspect. Drug Discov. Des. 1993, 1, 181-192.
11. De Clercq, E. HIV-1 specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med. Res. Rev. 1993, 13, 229-258.
12. De Clercq, E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med. Res. Rev. 1996, 16, 125-157.
13. De Clercq, E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. 1998, 38, 153-179.
14. Fuzeon brand enfuvirtide (T-20). http://www.aidsmeds.com/drugs/T-20.htm.
15. Lalezari, J.P.; Henry, K.; O'Hearn, M.; Montaner, J.S.; Piliero, P.J.; Trottier, B.; Walmsley, S.; Cohen, C.; Kuritzkes, D.R.; Eron, J.J. Jr; Chung, J.; DeMasi, R.; Donatacci, L.; Drobnes, C.; Delehanty, J.; Salgo, M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in north and south america. N. Engl. J. Med. 2003, 348, 2175-2185.
16. De Clercq, E. New developments in anti-HIV chemotherapy. Biochim. Biophys. Acta 2002, 1587, 258-275.
17. LaBranche, C.C.; Galasso, G.; Moore, J.P.; Bolognesi, D.P.; Hirsch, M.S.; Hammer, S.M. HIV fusion and its inhibition. Antiviral Res. 2001, 50, 95-115.
18. Butera, S.T. Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities. Antiviral Res. 2000, 48, 143-176.
19. Gulik, R.M. New antiretroviral drugs. Clin. Microbiol. Infect. 2003, 9, 186-193.
20. Cooley, L.A.; Lewin, S.R. HIV-1 cell entry and advances in viral entry inhibitor therapy. J. Clin. Virol. 2003, 26, 121-132.
21. Katz, R.A.; Skalka, A.M. The retroviral enzymes. Annu. Rev. Biochem. 1994, 63 133-173.
22. Vaishnav, Y.N.; Wong-Staal, F. The biochemistry of AIDS. Annu. Rev. Biochem. 1991, 60, 577-630.
23. Basu, A.; Basu, S.; Modak, M. J. Structure-activity analyses of HIV-1 reverse transcriptase. Biochem. Biophys. Res. Commun. 1992, 183, 1131-1138.
24. Rodgers, D.W.; Gamblin, S.J.; Harris, B.A.; Ray, S.; Culp, J.S.; Hellmig, B.; Woolf, D.J.; Debouck, C.; Harrison, S.C. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 1222-1226.
25. Hsiou, Y.; Ding, J.; Das, K.; Clark, A.D. Jr.; Hughes, S.H.; Arnold, E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 1996, 4, 853-860.
26. Jacobo-Molina, A.; Ding, J.; Nanni, R.G.; Clark, A.D. Jr.; Lu, X.; Tantillo, C.; Williams, R.L.; Kamer, G.; Ferris, A.L.; Clark, P.; Hizi, A.; Hughes, S. H.; Arnold, E. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 6320-6324.
27. Huang, H.; Chopra, R.; Verdine, G.L.; Harrison, S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998, 282, 1669-1675.
28. Ren, J.; Esnouf, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, I.; Keeling, J.; Darby, G.; Jones, Y.; Stuart, D.; Stammers, D. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Struct. Biol. 1995, 2, 293-302.
29. Wang, J.; Smerdon,.S.J.; Jager, J.; Kohlstaedt, L.A.; Rice, P.A.; Friedman, J.M.; Steitz, T.A. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 7242-7246.
30. Amacker, M.; and Hübscher, U. Chimeric HIV-1 and feline immuno-deficiency virus reverse transcriptases: critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerases. J. Mol. Biol. 1998, 278, 757-765.
31. Harris, D.; Lee, R.; Misra, H.S.; Pandey, P.K.; Pandey, V.N. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer. Biochemistry 1998, 37, 5903-5908.
32. Rattner, L.; Haseltine, W.; Patarca, R.; Livak, K.W.; Starcich, B.; Josephs, S.F.; Doran, E.R.; Rafalski, J.A.; Whitehorn, E.A.; Baumeister, K.; Ivanoff, L.; Petteway Jr, S.R.; Pearson, M.L.; Lautenberg, J.A.; Papas, T.S.; Ghrayeb, J.; Chang, N.T.; Gallo, R.C.; Wong-Staal, F. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985, 313, 277-284.
33. Pelletier, H.; Sawaya, M.A.; Kumar, A.; Wilson, S.H.; Krant, J. Structures of ternary complexes of rat DNA polymerase β, a DNA template-primer, and ddCTP. Science 1994, 264, 1891-1893.
34. Steitz, T.A. DNA and RNA-dependent DNA polymerases. Current Opinion in Structural Biology 1993, 3, 31-38.
35. Restle, T.; Müller, B.; and Goody, R.S. Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention. J. Biol. Chem. 1990, 265, 8986-8988.
36. Müller, B.; Restle, T.; Weiss, S.; Gautel, M.; Sczakiel, G.; Goody, R.S. Co-expression of the subunits of the heterodimer of HIV-1 reverse transcriptase in Escherichia coli. J. Biol. Chem, 1989, 264, 13975-13978.
37. Restle, T.; Müller, B.; Goody, R.S. RNase H activity of HIV reverse transcriptases is confined exclusively to the dimeric forms. FEBS Lett. 1992, 300, 97-100.
38. Morris, M.C.; Berducon, C.; Mery, J.; Heitz, F.; Divita, G. The thumb domain of the p51-subunit is essential for activation of HIV reverse transcriptase. Biochemistry 1999, 38, 15097-15103.
39. Divita, G.; Restle, T.; Goody, R.S. Characterization of the dimerization process of HIV-1 reverse transcriptase heterodimer using intrinsic protein fluorescence. FEBS Lett. 1993, 324, 153-158.
40. Divita, G.; Rittinger, K.; Geourjon, C.; Deléage, G.; Goody, R.S. Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two step process. J. Mol. Biol. 1995, 245, 508-521.
41. Balzarini, J.; De Clercq E. Analysis of inhibition of retroviral reverse transcriptase. Methods Enzymol 1996, 275, 472-502.
42. Fridland, A. Tenofovir, Gilead Sciences Inc. Curr. Opin. Anti-infect. Invest. Drugs. 2000, 2, 295-301.
43. De Clercq, E. New developments in anti-HIV chemotherapy. Current Medicinal Chemistry 2001, 8, 1543-1572.
44. Tantillo, C.; Ding, J.; Jacobo-Molina, A.; Nanni, R. G.; Boyer, P.L.; Hughes, S. H.; Pauwels, R.; Andries, K.; Janssen, P.A.J.; Arnold, E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 1994, 243, 369-387.
45. Nanni, R.G.; Ding, J.; Jacobo-Molina, A.; Hughes, S.H.; Arnold, E. Review of HIV-1 reverse transcriptase three-dimensional structure: Implications for drug design. Perspect. Drug Discov. Des. 1993, 1, 129-150.
46. Smerdon, S.J.; Jäger, J.; Wang, J.; Kohlstaedt, L.A.; Chirino, A.J.; Friedman, J. M.; Rice, P.A.; Steitz, T.A. Structure of the binding site for non-nucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 1994, 91, 3911-3915.
47. Esnouf, R.; Ren, J.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature Struct. Biol. 1995, 2, 302-308.
48. Spence, R.A.; Kati, W.M.; Anderson, K.S.; Johnson, K.A. Mechanism of inhibition of HIV -1 reverse transcriptase by non-nucleoside inhibitors. Science 1995, 267, 988-993.
49. Balzarini, J.; Pérez-Pérez, M.J.; San-Félix, A.; Schols, D.; Perno, C.F.; Vandamme, A.M.; Camarasa, M.J.; De Clercq, E. 2′,5′-Bis-O -(tert-butyldimethylsilyl)-3′-spiro-5″-(4″ -amino-1″, 2″-oxathiole-2″,2-dioxide) pyrimidine (TSAO) nucleoside analogues: Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl. Acad Sci. USA 1992, 89, 4392-4396.
50. Camarasa, M.J.; Pérez Pérez, M. J.; San-Félix, A.; Balzarini, J.; De Clercq, E. 3′-Spironucleosides a new class of specific human immunodeficiency virus type 1 inhibitors: Synthesis and antiviral activity of [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-xylo and ribofuranose]-3′-spiro-5″-[4″-amino-1″,2″- oxathiole- 2″,2″,-dioxide](TSAO) pyrimidine nucleosides. J. Med. Chem. 1992, 35, 2721-2727.
51. Balzarini, J.; Pérez-Pérez, M-J.; San-Félix, A.; Velázquez, S.; Camarasa, M.J.; De Clercq, E. [2′,5′-Bis-O-(tert-butyldimethylsilyl)]-3′ -spiro-5″- (4″-amino-1″,2″-oxathiole-2″ 2″-dioxide) (TSAO) derivatives of purine and pyrimidine, nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1992, 36, 1073-1080.
52. Pérez-Pérez, M.J.; San-Félix, A; Balzarini, J.; De Clercq, E.; Camarasa, M.J. TSAO Analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-bis-O-(tert-butyldimethylsilyl)-β -D-ribofuranosyl] -3′-spiro-(5″-(4″-amino-1″ ,2″-oxathiole-2″,2″-dioxide) pyrimidine and pyrimidine-modified nucleosides. J. Med. Chem. 1992, 35, 2988-2995.
53. Pérez-Pérez, M.J.; San-Félix, A.; Camarasa, M.J.; Balzarini, J.; De Clercq, E. Synthesis of [1-[2-pm,5′-bis-O-(t-butyldimethylsilyl)-β-D-xylo- and β-D-ribofuranosyl] thymine]-3′-spiro-5″-[4″- amino- 1″,2″- oxathiole-2″,2″-dioxide] (TSAO). A novel type of specific anti-HiV agents. Tetrahedron Lett. 1992, 33, 3029-3032.
54. Balzarini, J.; Pérez-Pérez, M.J.; San-Félix, A.; Camarasa, M.J.; Barr, P.J.; De Clercq, E. Interaction of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with the novel HIV-1 specific nucleoside analogue 1-[2′,5′-bis-O-(tert-butyldimethylsilyl)-β -D-ribofuranosyl] -3′-spiro-5″-[4″-amino-1″ ,2″-oxathiole-2″,2″-dioxide]thymine (TSAO-T). Arch. Int. Phys. Biochem. Biophys. 1992, 100, B28.
55. Camarasa, M.J.; Pérez-Pérez, M.J.; Velázquez, S.; San-Félix, A.; Alvarez, A.; Ingate, S.; Jimeno, M.L.; Karlsson, A.; De Clercq, E.; Balzarini, J. TSAO derivatives: Highly specific inhibitors of human immunodeficiency virus type-1 (HIV-1) replication. Nucleosides Nucleotides 1995, 14, 585-594.
56. Balzarini, J.; Camarasa, M.J.; Karlsson, A. TSAO derivatives: Highly specific human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors. Drugs of the Future 1993, 18, 1043-1055.
57. Balzarini, J.; Pérez-Pérez, M.J.; San-Félix, A.; Camarasa, M.J.; Bathurst, I.C.; Barr, P.J.; De Clercq, E. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1 specific nucleoside analogue 2′,5′-bis-O-(t-butyldimethylsilyl)-3′-spiro-5″ -(4″-amino-1″, 2″-oxathiole-2″,2″-dioxide) thymine (TSAO-T). J. Biol. Chem. 1992, 267, 11831-11838.
58. Balzarini, J.; Karlsson, A.; Vandamme, A,M.; Pérez-Pérez, M.J.; Zhang, H.; Vrang, L.; Oberg, B.; Backbro, K.; Unge, T.; San-Félix, A.; Velázquez, S.; Camarasa, M. J.; De Clercq, E. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2-pm,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″ -(4″-amino-1″, 2″-oxathiole-2″,2″-dioxide ]-β-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 1993, 90, 6952-6956.
59. Balzarini, J.; Velázquez, S.; San-Félix, A.; Karlsson, A.; Pérez-Pérez, M.J.; Camarasa, M.J.; De Clercq, E. The HIV-1-specific TSAO-purine analogues show a resistance spectrum that is different from that of the HIV-1-specific non-nucleoside analogues. Mol. Pharmacol. 1993, 43, 109-114.
60. Balzarini, J.; Karlsson, A.; Pérez-Pérez, M.J.; Vrang, L.; Walbers, J.; Zhang, H.; Öberg, B.; Vandamme, A.M.; Camarasa, M.J.; De Clercq, E. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology 1993, 192, 246-253.
61. Camarasa, M.J.; San-Félix, A.; Pérez-Pérez, M.J.; Velázquez, S.; Alvarez, R.; Chamorro, C.; Jimeno, M.L.; Pé rez, C.; Gago, F.; De Clercq, E.; Balzarini, J. HIV-1 specific reverse transcriptase inhibitors: why are TSAO-nucleosides so unique?. J. Carbohyd. Chem. 2000, 19, 451-469.
62. Camarasa, M.J.; Pérez-Pérez, M.J.; Velázquez, S.; San-Félix, A, Alvarez, R.; Ingate, S.; Jimeno, M.L.; De Clercq, E.; Balzarini, J. An overview of TSAO-T derivatives, a " peculiar" class of HIV-1 specific RT inhibitors. In Bentley, P.H. and O'Hanlon, PJ (Eds). Antiinfectives. Recent advances in chemistry and structure-activity relationships. Ch. 18 (pp.259-268). 1997. The Royal Society of Chemistry.
63. Velázquez, S.; Jimeno, M.L.; Camarasa, M.J.; Balzarini, J. Synthesis of [1-[3′,5′-bis-O-(tert-butyldimethylsilyl)-β -D-arabino- and -β-D - ribofuranosyl] cytosine] - 2′- spiro- 5″ - [4″-amino-1″,2″-oxathiole-2″,2″ -dioxide]. Analogue of the highly specific anti-HIV-1 agent TSAO-T. Tetrahedron, 1994, 50, 11013-11022.
64. Ingate, S.; Pérez-Pérez, M.J.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. Synthesis and anti-HIV-1 activity of novel TSAO-T derivatives modified at the 2′- and 5′-positions of the sugar moiety. Antiviral Res. 1995, 27, 281-299.
65. Chamorro, C.; Pérez-Pérez, M.J.; Rodríguez-Barrios, F.; Gago, F.; De Clercq, E.; Balzarini, J.; San-Félix, A.; Camarasa, M.J. Exploiting the role of the 5′-position of TSAO-T. Synthesis and anti-HIV evaluation of novel TSAO-T derivatives. Antiviral Res. 2001, 50, 207-222.
66. San-Félix, A.; Chamorro, C.; Pérez-Pérez, M.J.; Velázquez, S.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. Synthesis of novel 5′-substituted TSAO-T analogues with anti-HIV-1 activity. J. Carbohydr. Chem. 2000, 19, 635-640.
67. Velázquez, S.; San-Félix, A.; Pérez-Pérez, M.J.; Balzarini, J.; De Clereq, E.; Camarasa, M.J. TSAO analogues. 3. Synthesis and anti-HIV-1 activity of 2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl- 3′-spiro-5″-(4″-amino-1″,2″ -oxathiole-2″,2″-dioxide) purine and purine-modified nucleosides. J. Med. Chem. 1993, 36, 3230-3239.
68. San-Félix, A.; Velázquez, S.; Pérez-Pérez, M.J.; Balzarini, J.; De Clercq, E.; Camarasa, M.J. Novel series of TSAO-T derivatives. Synthesis and anti-HIV-1 activity of 4-, 5- and 6-substituted pyrimidine analogues. J. Med. Chem. 1994, 37, 453-460.
69. Alvarez, R.; Velázquez, S.; San-Félix, A.; Aquaro, S.; De Clercq, E.; Perno, C.F.; Karlsson, A.; Balzarini, J.; Camarasa, M.J. 1,2,3-Triazole-[[2′, 5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3′ -spiro-5″- (4″-amino-1″,2″-oxathiole-2″ ,2″-dioxide) (TSAO) analogues: Synthesis and anti-HIV-1 activity. J. Med. Chem. 1994, 37, 4185-4194.
70. San-Félix, A.; Alvarez, R.; Velázquez, S.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. Synthesis and anti-HIV-1 activity of 4- and 5-substituted 1,2,3-triazole-TSAO derivatives. Nucleosides Nucleotides, 1995, 14, 595-598.
71. Chamorro, C.; De Clercq, E.; Balzarni, J.; Camarasa, M.J.; San Félix, A. TSAO-T analogues bearing amino acids at position N-3 of thymine: synthesis and anti-human immunodeficiency virus activity. Antiviral Chem. Chemother. 2000, 11, 61-69.
72. Velázquez, S.; Alvarez, A.; Pérez, C.; Gago, F.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkylcarbamoyl 1,2,3-triazole-TSAO analogues. Antiviral Chem. Chemother. 1998, 9, 481-489.
73. Velázquez, S.; Chamorro, C.; Pérez-Pérez, M.J.; Alvarez, R.; Jimeno, M.L.; Martin-Domenech, A.; Pérez, C.; Gago, F.; de Clercq, E.; Balzarini, J.; San-Félix, A.; Camarasa, M.J. Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase. J. Med. Chem. 1998, 41, 4636-4647.
74. Balzarini, J.; Pérez-Pérez, M.J.; San-Félix, A.; Velázquez, S.; Camarasa, M.J.; Vandamme, A.M.; Karlsson, A.; De Clercq, E. TSAO Derivatives. A novel class of HIV-1-specific inhibitors. Proceedings of the Third International Symposium on the chemical synthesis of Antibiotics and Related Microbial Products, Kloster Banz, Germany, September 20-25, 1992, In: Krohn K, Kirs H, Maas RH, eds. Antibiotics and antiviral compounds, chemical synthesis and modifications. 1993.
75. Jonckheere, H.; Taymans, J.M.; Balzarini, J.; Velázquez, S.; Camarasa, M.J.; Desmyter, J.; De Clercq, E.; Anne, J. Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′ -spiro-5″-(4″-amino-1″,2″- oxathiole-2″ ,2″-dioxide)](TSAO) derivatives is determined by the mutation Glu138→Lys on the p51 subunit. J. Biol. Chem. 1994, 269, 25255-25258.
76. Boyer, P.L.; Ding, J.; Arnold, E.; Hughes, S.H. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1994, 38, 1909-1914.
77. Alvarez, R.; Jimeno, M.L.; Pérez-Pérez, M.J.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. Synthesis and and anti-human immunodeficiency virus type 1 activity of novel 3′-spiro nucleoside analogues of TSAO-T. Antiviral Chem. Chemother. 1997, 8, 507-517.
78. Alvarez, R.; Jimeno, M.L.; Gago, F.; Balzarini, J.; Pérez-Pérez, M.J.; Camarasa, M.J. Novel 3′-spiro nucleoside analogues of TSAO-T. Part II. A comparative study based on NMR conformational analysis in solution and theoretical calculations. Antiviral Chem. Chemother. 1998, 9, 333-340.
79. Alvarez, R.; San-Félix, A.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. Novel TSAO derivatives. Synthesis and anti-HIV-1 activity of allofuranosyl-TSAO-T analogues. Nucleosides Nucleotides 1996, 15, 349-359.
80. Ingate, S.; Camarasa, M.J.; De Clercq, E.; Balzarini, J. Synthesis and anti-HIV-1 activity of [1-[2′,5′-bis-O-(tert-butyldimethylsilyl)-β -L-ribofuranosyl]thymine] -3′-spiro-5″-(4″ -amino-1″,2″-oxathiole-2″,2″-dioxide) (L-TSAO-T), the L-enantiomer of the highly specific HIV-1 reverse transcriptase inhibitor TSAO-T. Antiviral Chem. Chemother. 1995, 6, 365-370.
81. Ingate, S.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. Novel L-lyxo and 5′-deoxy-5′-modified TSAO-T analogs: Synthesis and anti-HIV-1 activity. Antiviral Res. 1996, 32, 149-164.
82. Balzarini, J.; Naesens, L.; Bohman, C.; Pérez-Pérez, M.J.; San Félix, A.; Camarasa, M.J.; De Clercq, E. Metabolism and pharmacokinetics of the anti-HIV-1-specific inhibitor [1-[2′,5′-bis-O-(tert-butyldimethylsilyl) - β-D-ribofuranosyl]-3-N-methyl-thymine]-3′-spiro- 5″- (4″-amino-1″,2″-oxathiole -2″, 2″-dioxide . Biochem. Pharmacol. 1993, 46, 69-77.
83. Pauwels, R.; Andries, K.; Debyser, Z; Van Daele, P.; Schols, D.; Vandamme, A-M.; Stoffels, P.; De Vreese, K.; Woestenborghs, R.; Janssen, C.G.M.; Anné, J.; Cauwenbergh, G.; Desmyter, J.; Heykants, J.; Janssen, M.A.C.; De Clercq, E.; Janssen, P.A.J. Potent and highly selective HIV-1 inhibition by a new series of α-anilino phenyl acetamide (α-APA) derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 1993, 90, 1711-1715.
84. Vandamme, A-M.; Van Laethem, K.; De Clercq, E. Managing resistance to anti-HIV drugs. Drugs 1999, 57, 337-361.
85. Schinazi, R.F.; Larder, B.A.; Mellors, J.W. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News 1999, 7, 46-69.
86. Balzarini, J.; Karlsson, A.; Vandamme, A.M.; Pérez-Pérez, M.J.; Zhang, H.; Vrang, L.; Öberg, B.; Backbro, K.; Unge, T.; San-Félix, A.; Velázquez, S.; Camarasa, M. J.; De Clercq, E. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′ -spiro-5″-(4″-amino-1″, 2″-oxathiole-2″ ,2″-dioxide)]-β-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 6952-6956.
87. Balzarini, J.; Kleim, J.P.; Riess, G.; Camarasa, M.J.; De Clercq, E.; Karlsson, A. Sensitivity of (138 Glu →Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Biochem. Biophys. Res. Commun. 1994, 201, 1305-1312.
88. Balzarini, J.; Karlsson, A.; Camarasa, M.J.; De Clercq, E. HIV-1 strains selected for resistance against one partcicular class of HIV-1-specific reverse transcriptase inhibitors may retain sensitivity to other classes of HIV-1-specific inhibitors. Int. Antivir. News, 1993, 1, 66-68.
89. Balzarini, J.; Pelemans, H.; Pérez-Pérez, M.J.; San-Félix, A.; Camarasa, M.J.; De Clercq, E., Karlsson, A. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-dideoxy-3′-thiacytidine. Mol. Pharmacol. 1996, 49, 882-890.
90. Van Laethem, K.; Schmit, J.-C.; Pelemans, H.; Balzarini, J.; Witvrouw, M.; Pérez-Pérez, M.J.; Camarasa, M.J.; Esnouf, R.M.; Aquaro, S.; Cenci, A.; Perno, C.F.; Hermans, P.; Sprecher, S.; Ruiz, L.; Clotet, B.; Van Wijngaerden, E.; Van Ranst, M.; Desmyter, J.; De Clercq, E.; Vandamme, A.-M. Presence of 2′, 5′- bis - O - (tert-butyldimethylsilyl)- 3′-spiro- 5″-(4″-amino-1″,2″-oxathiole-2″,2″ -dioxide) (TSAO)-resistant virus strains in TSAO-unexperienced HIV patients. AIDS Res. Hum. Retrovir. 2000, 16, 825-833.
91. Pelemans, H., Aertsen, A.; Van Laethem, K.; Vandamme, A-M.; De Clercq, E.; Pérez-Pérez, M.J.; San-Félix, A.; Velázquez, S.; Camarasa, M.J.; Balzarini, J. Site-Directed Mutagenesis of Human Immunodeficiency Virus Type 1 Reverse Transcriptase at Amino Acid Position 138. Virology 2001, 280, 97-105.
92. Berkhout, B.; van Hemert, F.J. The unusual nucleotide content of the HIV RNA genome results in a biased amino acid composition of HIV proteins Nucleic Acids Res. 1994, 22, 1705-1711.
93. Bronson, E.C.; Anderson, J.N. Nucleotide composition as a driving force in the evolution of retroviruses. J. Mol. Evol. 1994, 38, 506-532.
94. Keulen, W.; Boucher, C.; Berkhout, B. Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins Antivir. Res. 1996, 31, 45-57.
95. Keulen, W.; Back, N.K.T.; van Wijk, A.; Boucher, C.; Berkhout, B. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type I reverse transcriptase. J. Virol. 1997, 71, 3346-3350.
96. Myers, G. Tenth anniversary perspectives on AIDS, HIV between past and future. AIDS Res. Hum. Retrovir. 1994, 10, 1317-1324.
97. Martinez, M.A.; Vartanian, J.-P.; Wain-Hobson, S. Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc. Natl. Acad. Sci. USA 1994, 91, 11787-11791.
98. Vartanian, J.-P.; Meyerhans, A.; Asj, B.; Wain-Hobson, S. Selection, recombination, and G→A hypermutation of human immunodeficiency virus type 1 genomes. J. Virol. 1991, 65, 1779-1788.
99. Vartanian, J.-P.; Meyerhans, A.; Sala, M.; Wain-Hobson, S. G→ A hypermutation of the human immunodeficiency virus type 1 genome evidence for dCTP pool imbalance during reverse transcription. Proc. Natl. Acad. Sci. USA 1994, 91, 3092-3096.
100. Balzarini, J.; Karlsson, A.; Velázquez, S.; Pérez-Pérez, M.J.; San-Félix, A.; Alvarez, R.; Perno, C.F.; Hatse, S.; Esnouf, R.; De Clecq, E.; Camarasa, M.J. Shifts in the endogenous 2′-deoxynucleotide pools affect the selection of mutant HIV strains resistant to non-nucleoside reverse transcriptase inhibitors. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-27 (1998); Abstract 26.
101. Balzarini, J.; Camarasa, M.J.; Pérez-Pérez, M.J.; San-Félix, A.; Velázquez, S.; Perno, C.F.; De Clecq, E.; Anderson, J.N.; Karlsson, A. Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV -1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV. J. Virol. 2001, 75, 5772-5777.
102. Balzarini, J. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochem. Pharmacol. 1999, 58, 1-27.
103. Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M.J.; Breslin, H.J.; Raeymaeckers, A.; Van Gelder, J.; Woestenborghs, R.; Heykants, J.; Schellekens, K.; Janssen, M.A.C.; De Clercq, E.; Janssen, P.A.J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990, 343, 470-474.
104. De Clercq E. HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 1994, 47, 155-169.
105. Balzarini, J.; Pérez-Pérez, M.J.; Velázquez, S.; San-Félix, A.; Camarasa, M.J.; De Clercq, E.; Karlsson, A. Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by the thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e. TSAO derivatives). Proc. Natl. Acad. Sci. USA 1995, 92, 5470-5474.
106. Balzarini, J.; Karlsson, A.; Pérez-Pérez, M.J.; Camarasa, M.J.; Tarpley, W.G.; De Clercq E. Treatment of Human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J. Virol. 1993, 67, 5353-5359.
107. Balzarini, J.; Karlsson, A.; Pérez-Pérez, M.J.; Camarasa, M.J.; De Clercq E. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology 1993, 196, 576-585.
108. Balzarini, J.; Karlsson, A.; Sardana, V.V.; Emini, E.A.; Camarasa, M.J.; De Clercq E. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C→C181I)RT HIV-1 mutants. Proc. Natl. Acad. Sci. USA 1994, 91, 6599-6603.
109. Velázquez, S.; Alvarez, R.; San-Félix, A.; Jimeno, M.L.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. Synthesis and Anti-HIV activity of [AZT]-[TSAO-T]and [AZT-[HEPT]dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase. J. Med. Chem. 1995, 38, 1641-1649.
110. Velázquez, S.; Tuñón, V.; Jimeno, M.L.; Chamorro, C.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. Potential multi-functional inhibitors of HIV-1 reverse transcriptase. Novel [AZT]-[TSAO-T]and [d4T]-[TSAO-T]heterodimers modified in the linker and in the dideoxynucleoside region. J. Med. Chem. 1999, 42, 5188-5196.
111. Chamorro, C.; Camarasa, M.J.; Pérez-Pérez, M.J.; De Clercq, E.; Balzarini, J.; San-Félix, A. An approach towards the synthesis of potential metal-chelating TSAO-T derivatives as bidentate inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antivir. Chem. Chemother. 1998, 9, 413-423.
112. Martell & Calvin. Chelate stability constants. In Chemistry of the Metal Chelate Compounds. Edited by Prentice-Hall, INC. New York: pp. 514-561 (1953).
113. Perrin, D.D. Stability constants of metal-ion complexes: part B Organic ligands. In IUPAC Chemical Data Series. no 22. Oxford: Pergamon Press (pp 273-280 and 1019-1020). 1979.
114. Velázquez, S.; Lobatón, E.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. "Double-drugs" [TSAO-T]-[PFA]. The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent esther bond. 15th International Conference on Antiviral Research. Prague, Czech Republic, March 17-21 (2002); Abstract 24.
115. Hopkins, A.L.; Ren, J.; Esnouf, R.; Willcox, B.E.; Jones, E.Y.; Ross, C.; Miyasaka, T.; Walker, R.T.; Tanaka, H.; Stammers, D.K.; and Stuart, D.I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 1996, 39, 1589-1600.
116. Esnouf, R.M.; Ren, J.; Hopkins, A.L.; Ross, C.K.; Jones, E. Y.; Stammers, D.K.; Stuart D.I. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc. Natl. Acad. Sci. USA 1997, 94, 3984-3989.
117. Sluis-Cremer, N.; Dmitrienko, G.I.; Balzarini, J.; Camarasa, M.J.; Parniak, M.A. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4″-amino-2″,2″-dioxo-1″,2″ -oxathiole-5″, 3′-[2′,5′ -bis-O-(tert-butyldimethylsilyl) -β -D-ribofuranosyl]]]-3-ethylthymine. Biochemistry 2000, 39, 1427-1433.
118. Rodríguez-Barrios, F.; Pérez, C.; Lobatón, E.; Velázquez, S.; Chamorro, C.; San-Félix, A.; Wrez-Pé rez, M.J.; Camarasa, M.J.; Pelemans, H.; Balzarini, J.;Gago, F. Identification of a putative binding site for [2′,5′ -Bis -O- (tert-butyldimethylsilyl) -β- D -ribofuranosyl]- 3′ -spiro-5″-(4″-amino- 1″,-2″- oxathiole -2″, 2″-dioxide) thymine (TSAO) derivatives at the p51-p66 interface of
119. Arion, D.; Fletcher, R.S.; Borkow, G.; Camarasa, M.J.; Balzarini, J.; Dmitrienko, G.I.; Parniak, M.A. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′ -spiro-5″-(4″-amino-1″, 2″-oxathiole-2″ ,2″-dioxide](TSAO). Mol. Pharmacol. 1996, 50, 1057-1064.
120. Balzarini, J.; Karlsson, A.; De Clercq, E. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. Mol. Pharmacol. 1993, 44, 694-701.
121. Lobatón, E.; Velázquez, S.; San-Félix, A.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. 4″-H-TSAO-T a novel prototype in the HIV-1 specific TSAO family. Nucleosides Nucleotides Nucleic Acids 2001, 20, 711-714.
122. Velázquez, S.; Lobatón, E.; Pérez-Pérez, M.J.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. 4th International Workshop on Drug Resistance and Treatment Strategies. Sitges, Spain, June 12-16 (2000); Abstract 10.
123. Bonache, M.C.; Chamorro, C.; Velázquez, S.; De Clercq, E.; Balzarini, J.; Camarasa, M.J.; San-Félix, A. N-3 substituted TSAO derivatives as a probe to explore the dimeric interface of HIV-1 reverse transcriptase. Nucleosides Nucleotides Nucleic Acids 2003, 22, 947-949.
124. Lobatón, E.; Rodríguez-Barrios, F.; Gago, F.; Pérez-Pérez, M.J.; De Clercq, E.; Balzarini, J.; Camarasa, M.J.; Velázquez, S. Synthesis of 3″-substituted TSAO-derivatives with anti-HIV-1 and anti-HIV-2 activity through an efficient palladium-catalyzed cross-coupling approach. J. Med. Chem. 2002, 45, 3934-3945.
125. Buckheit, R.W. Jr.; Watson, K.; Fliakas-Boltz, V.; Russell, J.; Loftus, T.L.; Osterling, M.C.; Turpin, J.A.; Pallansch, L.A.; White, E.L.; Lee, J.-W.; Lee, S.-H; Oh, J.-W.; Kwon, H.-S.; Chung, S.-G.; Cho, E.-H. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob. Agents Chemother. 2001, 45, 393-400.
126. Lobatón, E.; Velázquez, S.; Pérez-Pérez, M.J.; Jimeno, M.L.; San-Félix, A.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. "Second generation" of TSAO compounds directed against HIV-1 TSAO-resistant strains. Nucleosides Nucleotides Nucleic Acids 2001, 20, 707-710.
127. Calvo-Mateo, A.; Camarasa, M.J.; Díaz-Ortiz, A.; De las Heras, F.G. Novel aldol-type cyclocondensation of O-mesyl-(methylsulphonyl)-cyanohydrins. Application to the stereospecific synthesis of branched-chain sugars. J. Chem. Soc., Chem. Commun. 1988, 1114-1115.
128. Pérez-Pérez, M.J.; Camarasa, M.J.; Díaz-Ortiz, A.; San-Félix, A.; De las Heras, F.G. Stereospecific synthesis of branched-chain sugars by a novel aldol-type cyclocondensation. Carbohydr. Res. 1991, 216, 399-411.